Altimmune, Inc. - Common Stock (NQ: ALT )
6.370
+0.140
(+2.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
All News about Altimmune, Inc. - Common Stock
![](https://cdn.benzinga.com/files/images/story/2023/03/21/image28.jpeg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 21, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/03/21/doctor-gd46ada3af_1920.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Analyst Ratings for Altimmune
March 09, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Looking Into Altimmune's Return On Capital Employed
March 03, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For Altimmune
February 27, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/721127/bad-news-buy.jpg)
4 Analysts Have This to Say About Altimmune
January 20, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/12/20/alt_mark_composite_dark__5c44f870f266e303ff7a2e2a629fa798.png?width=1200&height=800&fit=crop)
Altimmune Touts Encouraging Data From Fatty Liver Disease Study
December 20, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/16/aapharma_5.png?width=1200&height=800&fit=crop)
Recent Selloff Is A 'Buying Opportunity' For This NASH Stock, Says Analyst
September 16, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 16, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 13, 2023
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/10/shutterstock_1259226739-scaled-e1666355474361.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image-lucid_group.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600b.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_26722.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/21/image12.jpg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/710145/cost-vs-value.jpg)
My 3 Top Biotech Stock Picks for 2023
November 22, 2022
Via The Motley Fool
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_26785.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/19/image_2.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/15/image_6.jpg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/14/bz-pharma_3.jpg?width=1200&height=800&fit=crop)
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
September 14, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/14/image32.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/26/image_1.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/23/image21.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_16972.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/15/image_2.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/14/image14.jpg?width=1200&height=800&fit=crop)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free